+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 34 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and clinical activity of EIK1001, a drug that targets Toll like receptor 78, given intravenously with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer NSCLC. This global, multicenter, double-blind, placebo-controlled study involves participants who have not received prior systemic therapy and aims to assess treatment effects in both squamous and non-squamous NSCLC types. The trial is conducted in two phases Phase 2 and Phase 3 and includes dose optimization, dose expansion, and confirmatory hypothesis testing. Participants are randomly assigned to one of three groups EIK1001 at one of two selected doses plus standard chemotherapy and pembrolizumab, or placebo plus standard chemotherapy and pembrolizumab. Chemotherapy regimens differ based on tumor histology, with pemetrexed plus carboplatin or cisplatin for non-squamous NSCLC, and carboplatin plus paclitaxel or nab-paclitaxel for squamous NSCLC. Treatments are administered intravenously, and the study is designed to evaluate safety and efficacy over time. During the study, participants undergo regular assessments to monitor progression-free survival, overall survival, and objective response, which are tracked for up to 6 to 10 years depending on the measure. Additional evaluations include adverse event incidence and duration of response. Participants are monitored closely with clinical visits throughout the study period, which may last several years, to ensure safety and collect data on treatment effects.

Age: 18Years +All GendersPhase 2Phase 3
42 locations
P

Actively Recruiting

Researchers are evaluating the safety and effects of the medicine Mevrometostat for treating RelapsedRefractory Small Cell Lung Cancer SCLC, Castration Resistant Prostate Cancer CRPC, and Follicular Lymphoma FL. This Phase 1 open-label study includes three parts, with Parts 1 and 2 closed for enrollment. Part 3, currently open, focuses on men with CRPC who have progressed after prior treatment. The study aims to understand how the study medicine behaves in the body and its impact on cancer. Participants in Part 3 receive Mevrometostat andor Enzalutamide. The study has two substudies a Bioequivalence BE substudy comparing two formulations of Mevrometostat, and a Drug-Drug Interaction DDI substudy with two cohorts. The BE substudy involves three single doses of Mevrometostat. The DDI substudy Cohort 1 takes Mevrometostat andor Itraconazole, and Cohort 2 combines Mevrometostat, Enzalutamide, and Itraconazole. After assessment phases, participants enter maintenance, taking Mevrometostat twice daily and Enzalutamide once daily until disease progression. Participants will visit the study center for dosing and monitoring, including evaluations of side effects, blood tests, and disease progression. The study measures dose-limiting toxicities, overall safety, and preliminary effectiveness using disease-specific criteria. Pharmacokinetics and patient-reported outcomes are also assessed at specific times. The study lasts approximately two years after the first participants visit, aiming to provide detailed safety and efficacy information.

Age: 18Years +All GendersPhase 1
85 locations
L

Actively Recruiting

Researchers are evaluating the safety and tolerability of TAK-861 in people with narcolepsy type 1 NT1. This study focuses on participants who have already been exposed to TAK-861 doses in previous clinical trials. The goal is to monitor how TAK-861 affects symptoms such as excessive daytime sleepiness and cataplexy episodes over a long period. All participants in this trial will receive TAK-861 tablets. Those who previously received a placebo will be randomly assigned to one of the TAK-861 dose groups. The study is a long-term extension conducted worldwide and is expected to last approximately five years or until the product is approved or the study is stopped. Participants may switch doses as needed and will attend multiple clinic visits, some of which can be done at home. Throughout the trial, participants will be regularly assessed for safety by tracking any treatment-emergent adverse events. Researchers will also measure changes in sleep latency, sleepiness scores, and cataplexy rates compared to baseline data from earlier trials. Follow-up assessments will take place four weeks after the final dose to monitor ongoing effects and ensure participant safety.

Age: 16Years - 70YearsAll GendersPhase 2Phase 3
52 locations
E

Actively Recruiting

Researchers are evaluating the combination of setidegrasib with chemotherapy in adults who have metastatic pancreatic cancer with a specific KRAS G12D gene mutation. This mutation leads to abnormal proteins that may promote cancer growth. The study aims to find out if adding setidegrasib to standard chemotherapy improves survival compared to chemotherapy with a placebo. This trial is a phase 3, randomized, double-blind study focused on treatment outcomes in this patient population. Participants will receive either setidegrasib or a placebo once weekly along with one of two chemotherapy regimens, mFOLFIRINOX or NALIRIFOX, given in 28-day cycles through intravenous infusion. The choice of chemotherapy is determined by the study doctor. Treatment continues until cancer progression, intolerable side effects, start of other cancer therapies, participant or doctor decision to stop, or death. NALIRIFOX is given only after safety is confirmed with setidegrasib in another study. During the study, participants will have regular safety checks, medical assessments, and evaluations of their wellbeing. Researchers will measure overall survival up to 3.5 years, time to cancer progression, quality of life, pain improvement, response rates, adverse events, and pharmacokinetics of setidegrasib. The study includes extensive monitoring of laboratory values, vital signs, and heart function with electrocardiograms throughout the trial period.

Age: 18Years +All GendersPhase 3
104 locations
E

Actively Recruiting

Researchers are evaluating dapirolizumab pegol DZP as an additional treatment alongside standard care medications for people with moderately to severely active systemic lupus erythematosus SLE. The study aims to determine if DZP can provide meaningful long-term improvement in disease activity compared to placebo. This is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by UCB Biopharma SRL. Participants are randomly assigned to receive either dapirolizumab pegol or a placebo throughout the treatment period. Both groups continue their standard of care medication during the trial. The treatment is administered at prespecified time points during the study, which lasts for 48 weeks. The study monitors disease activity and safety outcomes during this time. During the study, participants will attend regular visits to assess disease activity using measures such as the British Isles Lupus Assessment Group Disease Activity Index BILAG 2004 and the Systemic Lupus Erythematosus Disease Activity Index 2000 SLEDAI-2K. Researchers will also evaluate fatigue, glucocorticoid dose reduction, and record any treatment-emergent adverse events. Safety follow-up continues up to 54 weeks. Overall participation lasts nearly a year, including treatment and follow-up assessments.

Age: 16Years +All GendersPhase 3
245 locations
T

Actively Recruiting

Researchers are evaluating a new medicine called Sofetabart Mipitecan Sofe-M in a three-part clinical trial for people with certain types of ovarian, peritoneal, and fallopian tube cancers. The study focuses on patients with platinum-resistant cancer, whose disease worsened during or within six months after platinum chemotherapy, and those with platinum-sensitive cancer, whose disease remained controlled for at least six months after platinum treatment. The trial aims to determine if Sofe-M is more effective and to better understand its safety compared to standard treatments. Participants receive different treatments depending on their group. In Part A, patients with platinum-resistant disease receive Sofetabart Mipitecan or chemotherapy or Mirvetuximab Soravtansine, all given intravenously. In Parts B and C, patients with platinum-sensitive disease receive Sofetabart Mipitecan plus Bevacizumab or platinum-based chemotherapy plus Bevacizumab, also administered intravenously. The choice of chemotherapy is made by the investigator. Treatments are given in parallel groups. During the study, participants undergo regular assessments including imaging scans to monitor disease progression, safety evaluations, and quality of life questionnaires. Researchers measure progression-free survival as the primary outcome, along with overall survival, response rates, symptom changes, and drug levels in the blood. Each participants time in the study varies based on their response to treatment, with follow-up continuing up to 70 months after randomization to track outcomes and safety.

Age: 18Years +All GendersPhase 3
264 locations
I

Actively Recruiting

Healthy Volunteer

Researchers are evaluating whether short 10-minute exercise breaks during the school day can improve thinking skills, creativity, and emotional wellbeing in primary school children aged 11 to 12 years. The study compares aerobic exercise, strength-based exercise, and a seated control activity to see how each affects attention, working memory, creativity, and emotional state after mentally demanding tasks. This research aims to find effective ways to include physical activity in classrooms to support learning and wellbeing. Participants will be randomly assigned to one of three groups a control group that remains seated watching a low-demand silent video, a strength exercise group performing vigorous neuromuscular exercises following a Tabata format, or an aerobic exercise group doing moderate-intensity cardiovascular exercises with alternating upper and lower body movements. Each activity lasts about 10 minutes, including warm-up and cool-down, and is delivered via standardized instructional videos. Children will complete academic tasks before and assessments of cognitive function, creativity, and emotional state before and after the activity break. Physical fitness tests like strength, cardiorespiratory fitness, and body composition will also be conducted one week before the intervention. Researchers will measure outcomes such as self-perceived emotional state, executive function, and creativity throughout the morning, monitoring changes immediately after the breaks. The total participation involves baseline, pre-intervention, and post-intervention evaluations on a single study day.

Age: 11Years - 12YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are studying anxiety disorders, including specific phobia, panic disorder, agoraphobia, and social anxiety disorder. The goal is to evaluate the effectiveness of a new smartphone-guided, sensor-based in vivo exposure therapy combined with cognitive behavioral therapy CBT. This study compares traditional CBT with in vivo exposure to a version supported by the SYMPTOMS-JIT app, aiming to improve treatment and identify barriers to technology use in therapy. Participants will receive CBT involving psychoeducation, cognitive restructuring, emotion regulation, and coping strategies over 10 to 20 sessions. The core treatment includes repeated exposure to feared situations until distress decreases. One group receives standard in vivo exposure, while the other group uses the SYMPTOMS-JIT app to support their exposure therapy. The study includes randomized assignment to these two treatment groups. Participants will be assessed at baseline, after approximately 12 weeks of treatment, and at follow-ups after 3, 6, and 12 months. Assessments include interviews, fear and avoidance scales, and various anxiety and depression questionnaires. Researchers will monitor treatment effects, patient and therapist satisfaction, and therapy efficiency. The total participation involves initial treatment and long-term follow-up to evaluate lasting benefits and app usability.

Age: 18Years +All GendersPhase Not Applicable
1 location

1-10 of 34

1